Kinaxo Receives European Patent for Chemical Proteomics Technology
April 15, 2011
Kinaxo Receives European Patent for Chemical Proteomics Technology
Entitled "Proteome-wide quantification of small molecule binding to cellular target proteins," the patent encompasses the company's Cellular Target Profiling, KinAffinity, and Epigenetics Target Profiling services.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Evotec to Use PhosphoScout Platform in Oncology Biomarker Alliance with Roche
July 1, 2011 / ProteoMonitor - GSK to Buy Cellzome for $99M as Pharma Interest in Chemical Proteomics Continues to Build
May 18, 2012 / ProteoMonitor - Kinaxo, Takeda Ink Second Collaboration for Phosphoproteomics Research
March 18, 2011 / ProteoMonitor - AstraZeneca Taps Kinaxo to Conduct Mass Spec PTM Studies for Oncology Drug Development
January 7, 2011 / ProteoMonitor - Movers & Shakers
August 19, 2011 / ProteoMonitor